Vaxcyte Statistics
Total Valuation
Vaxcyte has a market cap or net worth of $10.42 billion. The enterprise value is $9.05 billion.
| Market Cap | 10.42B |
| Enterprise Value | 9.05B |
Important Dates
The next estimated earnings date is Tuesday, November 3, 2026, after market close.
| Earnings Date | Nov 3, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxcyte has 157.39 million shares outstanding. The number of shares has increased by 4.88% in one year.
| Current Share Class | 157.39M |
| Shares Outstanding | 157.39M |
| Shares Change (YoY) | +4.88% |
| Shares Change (QoQ) | +3.58% |
| Owned by Insiders (%) | 0.57% |
| Owned by Institutions (%) | 100.35% |
| Float | 145.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.48 |
| P/TBV Ratio | 3.78 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.72, with a Debt / Equity ratio of 0.04.
| Current Ratio | 5.72 |
| Quick Ratio | 5.48 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -36.51% and return on invested capital (ROIC) is -24.15%.
| Return on Equity (ROE) | -36.51% |
| Return on Assets (ROA) | -22.61% |
| Return on Invested Capital (ROIC) | -24.15% |
| Return on Capital Employed (ROCE) | -40.65% |
| Weighted Average Cost of Capital (WACC) | 10.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.10M |
| Employee Count | 507 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +56.24% in the last 52 weeks. The beta is 1.23, so Vaxcyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | +56.24% |
| 50-Day Moving Average | 61.35 |
| 200-Day Moving Average | 56.42 |
| Relative Strength Index (RSI) | 55.10 |
| Average Volume (20 Days) | 3,727,298 |
Short Selling Information
The latest short interest is 17.29 million, so 10.99% of the outstanding shares have been sold short.
| Short Interest | 17.29M |
| Short Previous Month | 16.13M |
| Short % of Shares Out | 10.99% |
| Short % of Float | 11.92% |
| Short Ratio (days to cover) | 12.15 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -1.17B |
| Pretax Income | -1.06B |
| Net Income | -1.06B |
| EBITDA | -1.15B |
| EBIT | -1.17B |
| Earnings Per Share (EPS) | -$7.65 |
Balance Sheet
The company has $1.49 billion in cash and $115.45 million in debt, with a net cash position of $1.37 billion or $8.71 per share.
| Cash & Cash Equivalents | 1.49B |
| Total Debt | 115.45M |
| Net Cash | 1.37B |
| Net Cash Per Share | $8.71 |
| Equity (Book Value) | 2.76B |
| Book Value Per Share | 19.05 |
| Working Capital | 1.28B |
Cash Flow
In the last 12 months, operating cash flow was -$881.23 million and capital expenditures -$39.84 million, giving a free cash flow of -$921.07 million.
| Operating Cash Flow | -881.23M |
| Capital Expenditures | -39.84M |
| Depreciation & Amortization | 16.51M |
| Net Borrowing | n/a |
| Free Cash Flow | -921.07M |
| FCF Per Share | -$5.85 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaxcyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -4.88% |
| Shareholder Yield | -4.88% |
| Earnings Yield | -10.21% |
| FCF Yield | -8.84% |
Analyst Forecast
The average price target for Vaxcyte is $117.30, which is 77.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $117.30 |
| Price Target Difference | 77.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |